Earnings Releases

WM TECHNOLOGY, INC. reported the fiscal year ended December 31, 2025 results: revenue $174.7 million, net income $3.3 million.

“Revenue of $174.7 million decreased from $184.5 million in the prior year. The decrease from the prior year was driven by continued headwinds across core markets, where ongoing pricing pressure and price deflation continued to compress client operating margins and constrain marketing budgets. ◦ Average monthly paying clients (1) of 5,190 was up from 5,077 in the prior year. The increase from the prior year period was largely due to new client acquisitions across certain developing markets, partially offset by a churn in more established markets. ◦ Average monthly revenues per paying client (2) of $2,805 decreased from $3,029 in the prior year. The decrease from the prior year period was due to spend declines in established markets driven by continued industry challenges, such as price deflation and ongoing consolidation. In addition, new clients acquired across certain markets had lower levels of average spend. • Net income decreased to $3.3 million from $12.2 million in the prior year”

WM TECHNOLOGY, INC. reported the fourth quarter ended December 31, 2025 results: revenue $43.1 million, net income $5.0 million.

“Revenue for the fourth quarter ended December 31, 2025 was $43.1 million, compared to $47.7 million in the prior year period. The decrease from the prior year period was driven by continued challenges across core markets, where ongoing pricing pressure continued to compress client operating margins and constrain marketing budgets. ◦ Average monthly paying clients (1) were 5,120, compared to 5,225 in the prior year period. The decrease from the prior year period was largely due to churn in more established markets, partially offset by new client acquisitions across certain developing markets. ◦ Average monthly revenues per paying client (2) of $2,804 decreased from $3,041 in the prior year period. The decrease from the prior year period was due to spend declines in established markets driven by continued industry challenges, such as price deflation and ongoing consolidation. In addition, new clients acquired across certain markets had lower levels of average spend. • Net loss was $5.0 m”

Oncology Institute, Inc. reported fiscal year ended December 31, 2025 results: revenue $502.7 million, net income Net loss of $60.6 million, EPS $(0.54) basic and diluted loss per share.

“million as of December 31, 2025 Year Ended 2025 Financial Highlights All comparisons are to the year ended December 31, 2024 unless otherwise noted • Consolidated revenue of $502.7 million, increased 27.8% • Gross profit of $76.4 million, an increase of 41.6% • Net loss of $60.6 million compared to $64.7 million • Basic and diluted loss per share of $(0.54) and”

Oncology Institute, Inc. reported fourth quarter ended December 31, 2025 results: revenue $142.0 million, net income Net loss of $7.5 million, EPS $(0.06) basic and diluted loss per share.

“MA lives in South Florida Fourth Quarter 2025 Financial Highlights All comparisons are to the quarter ended December 31, 2024 unless otherwise noted • Consolidated revenue of $142.0 million, increased 41.6% • Gross profit of $22.7 million, an increase of 55.2% • Net loss of $7.5 million compared to $13.2 million • Basic and diluted loss per share of $(0.06) compared”

Mission Produce, Inc. reported financial results for fiscal first quarter ended January 31, 2026.

“On March 12, 2026, Mission Produce, Inc. (the “Company”) announced its financial results for the quarter ended January 31, 2026.”

Open Lending Corp reported Year ended December 31, 2025 results: revenue Total revenue was $93.2 million during the year ended December 31, 2025, net income Net loss was $4.2 million during the year ended December 31, 2025.

“Total revenue was $93.2 million during the year ended December 31, 2025, compared to $24.0 million in the prior year . The year ended December 31, 2025 was impact ed by an increase of $0.4 million in estimated profit share revenues related to business in historic vintages as compared to a reduction of $96.1 million in the prior year .”

Open Lending Corp reported Quarter ended December 31, 2025 results: revenue Total revenue was $19.3 million during the fourth quarter of 2025, net income Net income was $1.7 million during the fourth quarter of 2025.

“Total revenue was $19.3 million during the fourth quarter of 2025, compared to $(56.9) million in the fourth quarter of 2024. The fourth quarter of 2025 was impacted by an insignificant change in estimated profit share revenues related to business in historic vintages as compared to a reduction of $81.3 million in the fourth quarter of 2024.”

Open Lending Corp reported fiscal quarter and year ended December 31, 2025 results: revenue Total revenue was $19.3 million during the fourth quarter of 2025, net income Net income was $1.7 million during the fourth quarter of 2025.

“On March 12, 2026, Open Lending Corporation (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2025.”

Lyell Immunopharma, Inc. reported financial results for the quarter and full year ended December 31, 2025.

“On March 12, 2026, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2025.”

American Outdoor Brands, Inc. reported fiscal year ending April 30, 2026 results: revenue net sales in the range of approximately $191 million to $193 million. Guidance reaffirmed.

“As such, we are maintaining our financial outlook and continue to expect fiscal 2026 net sales in the range of approximately $191 million to $193 million.”

Abacus Global Management, Inc. updated its the fourth quarter and full year ended December 31, 2025 guidance (initiated).

“On March 12, 2026, Abacus Global Management, Inc. ("Abacus" or "Company") announced the results of its operations and its financial condition for the annual period ended December 31, 2025.”

SkinHealth Systems Inc. reported financial results for fiscal quarter and year ended December 31, 2025.

“On March 12, 2026, The Beauty Health Company (the “Company”) issued a press release and will hold a conference call regarding its financial results for its fiscal quarter and year ended December 31, 2025.”

GPGI, Inc. reported Fiscal year ending December 31, 2026 results: revenue $2,183 to $2,228 million. Guidance initiated.

“Following annual guidance is based upon expectations for the combined results of CompoSecure and Husky Technologies. Guidance for Non-GAAP Pro Forma Adjusted EBITDA includes payment of the Resolute Holdings management fee. § Pro Forma Adj. Net Sales of $2,183 to $2,228 million § Pro Forma Adj. EBITDA of $620 to $650 million § Pro Forma Adj. Free Cash Flow of $325 to $375 million § Non-GAAP Year-end Net LTM Leverage less than 3.0x”

GPGI, Inc. reported Year ended December 31, 2025 results: revenue $462.1 million, net income ($136.0 million), EPS ($1.23).

“36.5%, up 640 basis points Full Year 2025 Results compared to prior year period unless otherwise noted; does not include results for Husky Technologies § Non-GAAP Net Sales of $462 million, up 10% § GAAP Net Loss of $136 million, down 48% § Pro Forma Adj. EBITDA of $171 million, up 24%, and Pro Forma Adj. EBITDA margin of 36.9%, up 408 basis points Recent Business”

GPGI, Inc. reported Fourth quarter ended December 31, 2025 results: revenue $117.7 million, net income $43.3 million, EPS $0.31.

“EBITDA Growth of 41% Fourth Quarter 2025 Results compared to prior year period unless otherwise noted; does not include results for Husky Technologies § Non-GAAP Net Sales of $118 million, up 17% § GAAP Net Income of $43 million, up 189% § Pro Forma Adj. EBITDA of $43 million, up 41%, and Pro Forma Adj. EBITDA margin of 36.5%, up 640 basis points Full Year 2025”

Montauk Renewables, Inc. reported the year ended 31 December 2025 results: revenue 176 382, EPS 0.01.

“AUDITED CONSOLIDATED RESULTS For the year ended 31 December 2025 Dollar amounts presented herein are in United States Dollars SALIENT FEATURES 2025 2024 Percentage change Revenue ($‘000) 176 382 175 736 0.4 % EBITDA ($‘000) 32 301 40 969 (21.2 %) Headline earnings ($‘000) 4 358 11 002 (60.4 %) Earnings per share ($) 0.01 0.07 (85.7 %)”

BuzzFeed, Inc. reported financial results for fourth quarter and full year ended December 31, 2025.

“On March 12, 2026, BuzzFeed, Inc. (the “Company”), issued a press release (the “Press Release”) announcing its financial results for the fourth quarter and full year ended December 31, 2025.”

United Homes Group, Inc. reported the fiscal year ended December 31, 2025 results: revenue $406.7 million.

“Home closings of 1,192, a decrease of 17% year over year compared to 1,431 home closings in 2024, resulting in revenue, net of sales discounts, of $406.7 million, a decrease of 12%”

United Homes Group, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $123.4 million, net income $3.2 million, EPS $0.05 per diluted share.

“For the fourth quarter 2025, net income was $3.2 million , or $0.05 per diluted share, which included a gain from the change in fair value of derivative liabilities of $22.1 million , with that change primarily due to changes in fair value on the Company's warrants due to fluctuation in the warrant price during the measurement period, representing a non-cash expense item, partially offset by deferred tax expense of $20.4 million related to a valuation allowance against the Company's net deferred tax assets. Net income for the fourth quarter 2024 was $0.7 million, or $0.01 per diluted share, which included a change in fair value of derivative liabilities of $38.0 million, partially offset by a predominantly non-cash loss on extinguishment of Convertible Notes of $45.6 million. Adjusted book value 2 , which excludes derivative liabilities and goodwill, was $78.3 million as of December 31, 2025 . Revenue, net of sales discounts, for the fourth quarter 2025 was $123.4 million, compared to”

Candel Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2025.

“On March 12, 2026, Candel Therapeutics, Inc. announced its financial results for the quarter and year ended December 31, 2025.”

Verano Holdings Corp. reported financial results for the quarter and fiscal year ended December 31, 2025.

“Verano Holdings Corp. (the “Company”) issued a press release (the “Earnings Press Release”) announcing its financial results for the quarter and fiscal year ended December 31, 2025.”

Century Therapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $109.2 million.

“first quarter of 2029. · Collaboration Revenue: Collaboration revenue generated through the company’s collaboration, option, and license agreement with Bristol-Myers Squibb was $109.2 million for the year ended December 31, 2025, compared to $6.6 million for the same period in 2024. · Research and Development (R&D) Expenses: R&D expenses were $95.7 million for the”

EverCommerce Inc. reported the quarter and year ended December 31, 2025 results: revenue $151.2 million, net income $5.7 million, EPS $0.03 per basic and diluted share.

“Revenue from continuing operations of $151.2 million”

Vivid Seats Inc. updated its the year ending December 31, 2026 guidance (reaffirmed).

“Financial Outlook for Full Year 2026 For the year ending December 31, 2026, Vivid Seats anticipates: • Marketplace GOV in the range of $2.2 billion to $2.6 billion • Adjusted EBITDA in the range of $30.0 million to $40.0 million*”

Vivid Seats Inc. updated its the first quarter ending March 31, 2026 guidance (initiated).

“Financial Outlook for Q1 2026 For the quarter ending March 31, 2026, Vivid Seats anticipates: • Marketplace GOV in the range of $570.0 million to $620.0 million • Adjusted EBITDA in the range of $8.0 million to $10.0 million* • Cash balance of $125.0 million to $135.0 million”

Vivid Seats Inc. reported the fiscal year ended December 31, 2025 results: revenue $570.8 million, net income Net loss of $721.5 million.

“Revenues of $570.8 million – down 26% from $775.6 million in 2024 • Net loss of $721.5 million – down $735.8 million from net income of $14.3 million in 2024”

Vivid Seats Inc. reported the fourth quarter ended December 31, 2025 results: revenue $126.8 million, net income Net loss of $428.7 million.

“Revenues of $126.8 million – down 37% from $199.8 million in Q4 2024 • Net loss of $428.7 million – down $424.2 million from a net loss of $4.4 million in Q4 2024”

reAlpha Tech Corp. reported the year ended December 31, 2025 results: revenue $4.5 million.

“Revenue increased 376% to $4.5 million, compared to $0.9 million in FY 2024.”

reAlpha Tech Corp. reported the fourth quarter ended December 31, 2025 results: revenue $0.9 million, net income $(4.8) million.

“Revenue increased 70% year over year to $0.9 million, compared to $0.5 million in the Q4 2024, driven primarily by increased revenue from mortgage brokerage transactions, subscription fees from AiChat’s AI conversational technologies, and revenues generated from Prevu’s realty services following its acquisition.”

Angel Studios, Inc. updated its the full year 2026 guidance (initiated).

“The Company anticipates a significantly narrowed Adjusted EBITDA loss of less than $25 million for the full year 2026.”

Angel Studios, Inc. reported the twelve months ended December 31, 2025 results: revenue $321.6 million. Guidance initiated.

“For the 2025 full year, revenue increased 233.2% to $321.6 million, compared to $96.5 million for the full year ended December 31, 2024.”

Angel Studios, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $109.9 million, net income $78.6 million, EPS ($0.47) per share. Guidance initiated.

“Total revenue was $109.9 million in the fourth quarter of 2025 and $321.6 million for the twelve months ended December 31, 2025, compared to $31.0 million and $96.5 million in the prior year periods, respectively. The quarterly increase in revenues was due to an increase in Angel Guild revenue of $54.7 million and theatrical release revenue, which increased by $19.6 million as a result of the success of the DAVID theatrical rollout. Gross Margin for the quarter was 60% compared to 58% a year ago in Q4. Selling and marketing for the fourth quarter of 2025 was $120.6 million, compared to $38.0 million for the 2024 comparable quarter. The increase was largely due to faster than expected Guild member growth and the marketing investment to support the DAVID release. Net loss was $78.6 million, or ($0.47) per share, in the fourth quarter of 2025, compared to a net loss of $37.2 million, or ($0.26) per share, in the fourth quarter of 2024.”

Chicago Atlantic Real Estate Finance, Inc. reported the year ended December 31, 2025 results: revenue $ 55,390,399, net income $ 36,010,478, EPS $ 1.68.

“For the year ended December 31, 2025 December 31, 2024 Total Amount Per Share Total Amount Per Share OPERATING RESULTS Net interest income $ 55,390,399 $ 2.58 $ 54,950,885 $ 2.56 Total expenses before provision for expected credit losses $ 18,813,870 $ 0.88 $ 18,320,604 $ 0.85 Net income - diluted $ 36,010,478 $ 1.68 $ 37,045,403 $ 1.72”

Chicago Atlantic Real Estate Finance, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $ 14,238,203, net income $ 8,157,249, EPS $ 0.38.

“For the three months ended December 31, 2025 September 30, 2025 December 31, 2024 Total Amount Per Share Total Amount Per Share Total Amount Per Share OPERATING RESULTS Net interest income $ 14,238,203 $ 0.66 $ 13,685,274 $ 0.64 $ 14,068,376 $ 0.69 Total expenses before provision for expected credit losses $ 5,981,137 $ 0.28 $ 4,193,515 $ 0.20 $ 5,682,193 $ 0.28 Net income $ 8,157,249 $ 0.38 $ 8,934,539 $ 0.42 $ 7,919,692 $ 0.39”

KinderCare Learning Companies, Inc. updated its fiscal year 2026 guidance (initiated).

“today announced financial results for the fourth quarter and fiscal year 2025, which ended January 3, 2026, and provided guidance for fiscal year 2026.”

KinderCare Learning Companies, Inc. reported the fourth quarter ended January 3, 2026 results: revenue $688.1 million, net income Net loss of $177.2 million, EPS net loss per common share, diluted of $1.50.

“Fourth Quarter 2025 Highlights • Revenue of $688.1 million • Loss from operations of $163.9 million • Net loss of $177.2 million and net loss per common share, diluted of $1.50”

ProFrac Holding Corp. reported Fourth Quarter 2025 results: revenue $437 million, net income $141 million. Guidance initiated.

“Fourth Quarter 2025 Results · Total revenue was $437 million compared to third quarter revenue of $403 million · Net loss was $141 million compared to net loss of $92 million in the third quarter”

ProFrac Holding Corp. reported Full Year 2025 results: revenue $1.94 billion, net income $356 million. Guidance initiated.

“Full Year 2025 Results · Total revenue was $1.94 billion compared to revenue of $2.19 billion in 2024 · Net loss was $356 million compared to net loss of $208 million in 2024”

Shimmick Corp reported the fiscal year ended January 2, 2026 results: revenue $493 million, net income $(26) million, EPS $(0.74) per diluted share.

“and fiscal year ended January 2, 2026. Highlights • Reported revenue of $100 million, which includes $84 million of Shimmick Projects revenue, for Q4 2025, and revenue of $493 million, which includes $397 million of Shimmick Projects revenue, for FY2025 o Shimmick Projects Q4 2025 revenue up 4% year over year o Shimmick Projects FY2025 revenue up 12% year over”

Shimmick Corp reported the fourth quarter ended January 2, 2026 results: revenue $100 million, net income $(3) million, EPS $(0.08) per diluted share.

“critical infrastructure construction services, today announced financial results for the fourth quarter and fiscal year ended January 2, 2026. Highlights • Reported revenue of $100 million, which includes $84 million of Shimmick Projects revenue, for Q4 2025, and revenue of $493 million, which includes $397 million of Shimmick Projects revenue, for FY2025 o”

Syra Health Corp updated its FY2026 guidance (initiated).

“2026 Financial Outlook ● The Company expects to achieve profitability by year-end 2026, driven by continued strong demand for its comprehensive population health solutions, disciplined cost management, and new contract wins.”

Syra Health Corp reported Q4 2025 results: net income ($135K), EPS ($0.01).

“Q4 and Full Year 2025 Financial Highlights ● Population Health revenue grew 157% year-over-year to $5.3 million in FY2025 from $2.1 million in FY2024, driven by demand for the Company's higher margin yielding population health solutions, including data analytics, health education and training. Q4 2025 Population Health revenue grew 128% year-over-year to $1.3 million, compared to $550K in Q4 2024. ● Earnings per share improved by $0.42 in FY2025 to ($0.08) from ($0.50) in FY2024. Q4 2025 EPS improved to ($0.01) from ($0.08) in Q42024, representing meaningful progress as the Company moves closer to profitability. ● Total operating expenses declined 37% to $3.4 million in FY2025 when compared to $5.4 million in FY2024. Q4 2025 operating expenses decreased 13% to $727K from $836K in Q4 2024. ● Net loss improved 76% to ($896K) in FY2025 from ($3.8M) in FY2024. Q4 2025 net loss was reduced 73% to ($135K) versus ($504K) in Q4 2024, reflecting a significantly improved cost structure. ● Gross”

Syra Health Corp reported FY2025 results: revenue $7,225,973, net income ($896,333), EPS ($0.08).

“Syra Health Corp Statements of Operations For the Years Ended December 31, 2025 and 2024 December revenues $ 7,225,973 $ 7,982,082 Cost of services 4,738,211 6,329,119 Gross profit 2,487,762 1,652,963 OPERATING EXPENSES: Salaries and benefits 1,500,688 2,718,743 Professional services 737,714 606,051 Research and development expenses 67,840 585,146 Selling, general and administrative expenses 1,065,376 1,445,170 Depreciation 20,468 62,738 Total operating expenses 3,392,086 5,417,848 Net loss from operations (904,324 ) (3,764,885 ) OTHER INCOME (EXPENSES): Interest income 21,261 21,247 Interest expense (13,270 ) (15,600 ) Total other income (expense) 7,991 5,647 NET INCOME (LOSS) $ (896,333 ) $ (3,759,238 ) Loss per common share, basic and diluted $ (0.08 ) $ (0.50 ) Weighted average number of common shares outstanding, basic and diluted 11,852,347 7,551,576”

Mineralys Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $154.7 million.

“Net loss was $154.7 million for the year ended December 31, 2025”

Mineralys Therapeutics, Inc. reported the quarter ended December 31, 2025 results: net income $32.2 million.

“Net loss was $32.2 million for the quarter ended December 31, 2025”

SURF AIR MOBILITY INC. updated its 2026 guidance (initiated).

“the Company is establishing 2026 revenue guidance 20 to 30 percent above the 2025 results.”

SURF AIR MOBILITY INC. reported full year ended December 31, 2025 results: revenue $106.6 million, net income $110.5 million.

“Revenue of $106.6 million for the full year 2025 decreased 10.8% compared to $119.4 million for the prior year.”

SURF AIR MOBILITY INC. reported fourth quarter ended December 31, 2025 results: revenue $26.4 million, net income $36.9 million.

“Revenue of $26.4 million for the fourth quarter of 2025 decreased 6% compared to $28.05 million for the same period of the prior year, meeting the Company’s expectation of $25.5 to $27.5 million.”

Silvaco Group, Inc. reported full year ended December 31, 2025 results: revenue $63.1 million, net income $41.2 million, EPS $1.39.

“Full Year 2025 Financial Results GAAP Financial Results: • Revenue of $63.1 million up 6% year-over-year. ◦ TCAD revenue of $30.0 million, down 25% year-over-year. ◦ EDA revenue of $23.4 million, up 60% year-over-year. ◦ SIP revenue of $9.7 million, up 98% year-over-year. • GAAP gross margin of 78%, down 154 basis points year-over-year. • GAAP operating loss of $45.9 million, compared to $40.3 million operating loss in FY 2024. • GAAP net loss of $41.2 million, compared to $39.4 million net loss in FY 2024. • GAAP basic and diluted net loss per share of $1.39, compared to basic and diluted net loss per share of $1.53 in FY 2024.”